PGT-M Explained: Single-Gene Testing Before Embryo Transfer
Key Takeaways
PGT-M combines IVF, blastocyst biopsy, and a bespoke lab assay built around a known single-gene (monogenic) familial variant. It lowers the chance of transferring an embryo affected by that specific condition. It does not predict implantation or live birth, and it does not rule out every other genetic or health risk.
Key evidence: ASRM committee opinion: indications and management of PGT-M (2023) ESHRE good practice recommendations for monogenic PGT (2020) ACOG committee opinion: preimplantation genetic testing (2020)
PGT-M: How to Reduce the Risk of Passing On a Serious Genetic Condition
This video was recorded in French. English and Arabic dubbed audio and subtitles are available from the YouTube player settings.
When a family already knows which specific gene variant is at stake, the central question is rarely “Can we screen for everything?” It is much more focused: how significantly can we lower the chance of passing down this particular inherited disease, without losing sight of the realistic limits of IVF?
PGT-M (preimplantation genetic testing for monogenic disorders), historically called PGD, is designed specifically for this purpose. The laboratory builds a targeted assay around the familial variant and, where needed, validated linked markers. That focus helps with embryo selection for one defined condition. It remains one part of IVF care and cannot predict every outcome of a pregnancy.
What is PGT-M?
PGT-M is a targeted molecular test performed on a small sample of cells taken from an embryo—typically at the day-5 or day-6 blastocyst stage. Its primary purpose is to identify whether an embryo has inherited a specific, known single-gene alteration, allowing the clinical team to prioritize unaffected embryos for transfer.
In daily clinical practice, the procedure builds upon a standard IVF framework: ovarian stimulation, egg retrieval, fertilization, and extended laboratory culture. Once an embryo reaches the blastocyst stage, embryologists perform a trophectoderm biopsy, carefully removing 5 to 10 cells from the outer layer destined to form the placenta. These cells are analyzed using an assay customized for your family’s exact mutation.
According to the ASRM Practice Committee guidance (2023), PGT-M can reduce the chance of transferring an embryo affected by the targeted monogenic disorder. Its scope is specific: it does not routinely assess chromosome copy number, which is the separate question addressed by PGT-A, and it cannot predict implantation or live birth.
Who is it used for?
PGT-M is considered when one or both prospective parents carry a confirmed pathogenic genetic variant that poses a significant risk of causing a severe inherited disease in their offspring.
PGT-M is commonly considered for:
- Autosomal recessive conditions: Such as cystic fibrosis, beta-thalassemia, sickle cell disease, and spinal muscular atrophy (SMA), when the reproductive risk arises from pathogenic variants in the same disease-associated gene. The variants may be the same or different.
- Autosomal dominant disorders: Such as Huntington’s disease, Marfan syndrome, or neurofibromatosis, where an affected parent may pass the variant on in 50% of pregnancies. Whether a child develops the condition can also depend on the condition and its penetrance.
- X-linked conditions: Such as fragile X syndrome or Duchenne muscular dystrophy.
- Hereditary cancer syndromes: Including familial BRCA1 and BRCA2 variants or Lynch syndrome, subject to regional ethical regulations.
A clear molecular genetics report is usually needed before the laboratory can design the test. A consumer screening result alone may not provide the variant details or family information needed for PGT-M. Depending on the case, the laboratory may also request samples from relatives with known genetic status to establish linkage.
How does the PGT-M process work?
The clinical pathway moves through seven distinct stages, linking clinical embryology with molecular genetics:
| Step | Clinical Phase | What Happens |
|---|---|---|
| 1 | Pre-cycle assay design | Genetic counseling, validation of familial variants, design of targeted probes and linkage markers |
| 2 | Ovarian stimulation & retrieval | Standard hormonal protocol followed by egg retrieval under mild sedation |
| 3 | Fertilization & culture | Fertilization in the IVF laboratory, often by ICSI when the laboratory protocol needs to minimise extraneous sperm DNA; culture to a day-5 or day-6 blastocyst |
| 4 | Trophectoderm biopsy | Removal of 5–10 trophectoderm cells; the blastocysts are immediately vitrified (frozen) |
| 5 | Targeted genetic testing | DNA amplification and analysis for the specific familial mutation |
| 6 | Embryo categorization | Classification of embryos as unaffected, carrier, affected, or inconclusive |
| 7 | Frozen embryo transfer (FET) | Individualised endometrial preparation and transfer of an embryo selected after counselling |
The pre-cycle phase is often the quiet bottleneck of the journey. The ASRM guidance (2023) says that custom test development is ideally completed before IVF begins; the ESHRE recommendations (2020) also describe validation before clinical use. In time-sensitive cases, the IVF and genetics teams may discuss embryo banking while the test is being prepared. Whether a cycle can start before preparation is complete, and when biopsy can occur, must be agreed with the specific PGT laboratory.
Why does preparation take time?
Developing a PGT-M test is not an off-the-shelf laboratory panel. Because human gene variants are diverse, the genetics laboratory must construct and validate a custom diagnostic strategy for each couple.
This process involves sequencing parental DNA samples, verifying linkage markers (short polymorphic DNA segments flanking the gene), and establishing positive and negative controls. In many instances, DNA samples from biological parents or previous children are needed to phase the chromosomes accurately.
This preliminary work may take a few weeks to a few months, depending on the family, the variant and the laboratory. It helps reduce technical risks such as allele dropout (ADO), in which one copy of a gene is not amplified in the test. Ask the laboratory for a case-specific timeline and for an explanation of how it handles an inconclusive result.
What PGT-M can and cannot do
Clear expectations prevent emotional exhaustion. Understanding both the diagnostic power and the technical boundaries of PGT-M allows couples to make grounded decisions.
What PGT-M can achieve:
- Substantially reduce the transmission risk of the targeted single-gene condition.
- Distinguish between affected and unaffected embryos in autosomal and X-linked conditions.
- Identify carrier embryos in autosomal recessive disorders when linkage phasing permits.
What PGT-M cannot do:
- It cannot guarantee that an embryo will implant or result in a live birth.
- It cannot detect unrelated chromosomal aneuploidies unless combined with a clinically indicated PGT-A test.
- It cannot produce embryos if ovarian response or laboratory fertilization is limited.
- It cannot promise that every completed cycle will yield an unaffected embryo ready for transfer.
In some treatment cycles, all available embryos may be affected by the targeted condition or arrest before biopsy. The ASRM guidance (2023) and ESHRE consortium data support discussing the possibility of no transferable embryo openly before stimulation medications begin. Furthermore, visual laboratory grading (such as 4AA or 3BB) reflects cell morphology only, not genetic health; see our guide on IVF embryo grading.
Why genetic counselling matters
Pre-test genetic counselling is an important clinical conversation, not an administrative formality. A genetic counsellor can explain the inheritance pattern, the limits of the result and possible incidental findings.
Counseling addresses key ethical and practical questions:
- How will an inconclusive result be managed, and—if PGT-A is also performed—how will a mosaic result be discussed?
- If the condition is autosomal recessive, is the couple comfortable transferring a healthy carrier embryo?
- What clinical and legal rules apply to testing, storage and embryo transfer in the country of treatment?
Rushing past these discussions often creates complex dilemmas later. Shared clarity before treatment provides peace of mind when laboratory reports arrive.
Practical planning for international patients
International planning usually starts with sharing complete genetic records securely with the IVF and PGT laboratories. Their review determines which samples are needed, whether relatives need to participate and whether a visit is required for treatment, biopsy or transfer.
The timing of stimulation, biopsy, results and a frozen embryo transfer varies between laboratories and treatment plans. Ask for a written, case-specific schedule before arranging travel. Complete laboratory reports, accurate variant nomenclature and prior genetic counselling records can make that review more efficient.
Questions worth discussing before deciding
Take this checklist to your consultation with your reproductive endocrinologist and clinical geneticist:
- What is the exact HGVS molecular nomenclature of our familial variant, and is it confirmed on formal laboratory documentation?
- Does the laboratory utilize direct sequencing, targeted PCR, or next-generation sequencing (NGS) with linkage analysis?
- What is the reported inconclusive or failure rate for our custom assay?
- In our inheritance pattern, what is our clinic’s protocol regarding the transfer of healthy carrier embryos?
- What contingency plan exists if no unaffected embryos are obtained from the first cycle?
- Why is confirmatory prenatal diagnosis (CVS or amniocentesis) still recommended during pregnancy, even with an unaffected PGT-M result?
- What legal boundaries apply to embryo testing, storage duration, and single-embryo transfer in our treatment country?
Clinical Note
PGT-M is highly targeted, but it does not reduce the chance of a diagnostic error to zero. The residual risk depends on the variant, the available family markers and the laboratory method.
ACOG (2020) and ASRM (2023) recommend that prenatal testing be offered after PGT-M. This gives parents information and a choice; it does not require them to accept an invasive procedure. NIPT does not replace CVS or amniocentesis when the aim is to confirm a specific familial monogenic variant.
The meaning of a carrier result depends on the inheritance pattern and the condition. In a classic autosomal recessive condition, an embryo with one disease-associated variant is usually an unaffected carrier. If only unaffected carrier embryos are available, transfer can be discussed after genetic counselling. A future child may be able to pass the variant on.
Test preparation should be discussed early. In selected time-sensitive cases, embryo banking may be discussed while the genetics laboratory completes its work-up. The laboratory, IVF team and patients should agree on the testing and biopsy plan before it proceeds.
Related reading in English:
- Can PGT be used for sex selection?
- IVF embryo grading explained
- IVF risks and practical considerations
FAQ
Is PGT-M the same as standard IVF?
No. IVF is the platform. PGT-M adds biopsy and a targeted test for a known inherited condition.
Does PGT-M mean a baby will be healthy?
No. It lowers the chance of transferring an embryo affected by the targeted disorder. It does not assess every other genetic or health risk, and it cannot predict pregnancy or live birth.
Can PGT-M be done without knowing the exact mutation?
Usually no. The laboratory needs a clearly identified familial variant — or another validated strategy — first.
Can a cycle end with no transferable embryo?
Yes. Embryos may not develop, all may be affected, or no unaffected embryo may be available.
Is prenatal testing still needed after PGT-M?
Often yes. Many programmes still offer confirmatory prenatal testing because embryo testing, while highly useful, is not treated as infallible.
Is PGT-M the same as PGT-A?
No. PGT-M asks about one monogenic disease. PGT-A asks about chromosome copy number. They answer different questions and are combined only when clinically justified.
Sources
- Practice Committee of the American Society for Reproductive Medicine (ASRM). “Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion.” Fertil Steril. 2023; 120(1): 61-71. PMID: 37162432
- ESHRE PGT-M Working Group. “ESHRE PGT Consortium good practice recommendations for the detection of monogenic disorders.” Hum Reprod Open. 2020; 2020(3): hoaa018. PMID: 32500103
- American College of Obstetricians and Gynecologists (ACOG). “Preimplantation Genetic Testing: ACOG Committee Opinion, Number 799.” Obstet Gynecol. 2020; 135(3): e133-e137. PMID: 32080053
- Gutiérrez-Mateo C et al. “Preimplantation genetic diagnosis of single-gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States.” Fertil Steril. 2009; 92(5): 1544-1556. PMID: 18937943
- De Rycke M et al. “ESHRE PGD Consortium data collection XIV-XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013.” Hum Reprod. 2017; 32(10): 1974-1994. PMID: 29117384
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.